ClinicalTrials.gg
CompletedNCT05567159Updated Oct 4, 2024Results posted

A Study of Donanemab (LY3002813) in Healthy Participants

A Phase 1 interventional study of Donanemab in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-04.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The main purpose of this study is to assess how fast donanemab (LY3002813) gets into the blood stream and how long it takes the body to remove it when administered as single dose in healthy participants. The study will also evaluate the safety and tolerability of donanemab. The study will last up to approximately 22 weeks.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation
  • Have a (BMI) of 19.0 and 32.0, kilograms per meter squared (kg/m²), inclusive.
  • Females of will be excluded from the study.

Exclusion criteria

Exclusion Criteria:

  • Have allergies to either humanized monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisolone
  • Have a history within the past 5 years of a primary or recurrent malignant disease
  • Have used over-the-counter or prescription medications, including herbal medication, within 7 days prior to dosing
  • Are pregnant or intend to become pregnant or to breastfeed during the study
  • Smoke more than 10 cigarettes per day or are unable to abide by investigative site smoking restrictions
  • Have a history of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous malformation, carotid, carotid artery occlusion, stroke or epilepsy or family history of dementia or Down's syndrome
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Donanemab

    Participants received a 350 milligrams (mg) intravenous (IV) infusion of donanemab every two weeks for six treatment periods (1 to 6), each lasting two weeks. Treatments were administered on the first day of each period, i.e., days 1, 15, 29, 43, 57, and 71.

    Drug: Donanemab

Interventions

  • Administered IV.

    Also known as: LY3002813

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Four Weeks (AUC[0-4 Weeks]) of Donanemab (i.e) Period 2, Period 4, Period 6.

    As per the prespecified analysis, AUC\[0-4 weeks\] will be calculated as the sum of AUC0-2weeks for: * treatment period 1 and 2 (dosing days 1, 15 respectively) represented as period 2 * treatment period 3 and 4 (dosing days 29, 43 respectively) represented as period 4 * treatment period 5 and 6 (dosing days 57, 71 respectively) represented as period 6.

    Time frame: Predose, end of infusion, 24, 48, 72, 96, 168, 336 hours post-dose on days 1, 15, 29, 43, 57, 71

  2. PK: Maximum Observed Concentration During a Dosing Interval at Steady State (Cmax, ss) of Donanemab

    PK: Cmax, ss of Donanemab

    Time frame: Predose, end of infusion, 24, 48, 72, 96, 168, 336 hours post-dose on day 71

  3. PK: Area Under the Concentration Versus Time Curve During a Dosing Interval at Steady State (AUCτ,ss) of Donanemab

    PK: AUCτ,ss of Donanemab

    Time frame: Predose, end of infusion, 24, 48, 72, 96, 168, 336 hours post-dose on day 71

07

Results

Posted Oct 4, 2024

Participant flow

Participant flow — Overall Study
MilestoneDonanemab
Started42
Received at least one iv infusion of donanemab42
Completed34
Not completed8
Withdrew: Adverse event4
Withdrew: Physician decision3
Withdrew: Protocol deviation1

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Four Weeks (AUC[0-4 Weeks]) of Donanemab (i.e) Period 2, Period 4, Period 6.

As per the prespecified analysis, AUC\[0-4 weeks\] will be calculated as the sum of AUC0-2weeks for: * treatment period 1 and 2 (dosing days 1, 15 respectively) represented as period 2 * treatment period 3 and 4 (dosing days 29, 43 respectively) represented as period 4 * treatment period 5 and 6 (dosing days 57, 71 respectively) represented as period 6.

Time frame:
Predose, end of infusion, 24, 48, 72, 96, 168, 336 hours post-dose on days 1, 15, 29, 43, 57, 71
Reported as:
Geometric mean · microgram*hour per milliliter (μg*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Four Weeks (AUC[0-4 Weeks]) of Donanemab (i.e) Period 2, Period 4, Period 6.
microgram*hour per milliliter (μg*h/mL)Donanemab
Period 217300 ± 23
Period 415400 ± 32
Period 615500 ± 45
PrimaryPK: Maximum Observed Concentration During a Dosing Interval at Steady State (Cmax, ss) of Donanemab

PK: Cmax, ss of Donanemab

Time frame:
Predose, end of infusion, 24, 48, 72, 96, 168, 336 hours post-dose on day 71
Reported as:
Geometric mean · μg/mL
PK: Maximum Observed Concentration During a Dosing Interval at Steady State (Cmax, ss) of Donanemab
μg/mLDonanemab
PK: Maximum Observed Concentration During a Dosing Interval at Steady State (Cmax, ss) of Donanemab112 ± 21
PrimaryPK: Area Under the Concentration Versus Time Curve During a Dosing Interval at Steady State (AUCτ,ss) of Donanemab

PK: AUCτ,ss of Donanemab

Time frame:
Predose, end of infusion, 24, 48, 72, 96, 168, 336 hours post-dose on day 71
Reported as:
Geometric mean · μg*h/mL
PK: Area Under the Concentration Versus Time Curve During a Dosing Interval at Steady State (AUCτ,ss) of Donanemab
μg*h/mLDonanemab
PK: Area Under the Concentration Versus Time Curve During a Dosing Interval at Steady State (AUCτ,ss) of Donanemab7590 ± 50

Adverse events

Collected over Baseline to Week 22. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donanemab0/42 (0%)0/42 (0%)22/42 (52.4%)
Most frequent other events
Most frequent other events
EventDonanemab
HeadacheNervous system disorders13/42
Infusion related reactionInjury, poisoning and procedural complications7/42
Upper respiratory tract infectionInfections and infestations4/42
Blood creatine phosphokinase increasedInvestigations3/42

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Donanemab
Mean28.9 ± 5.4
Sex: Female, Male
Sex: Female, Male(Participants)Donanemab
Female0
Male42
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Donanemab
Hispanic or Latino14
Not Hispanic or Latino28
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Donanemab
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American10
White28
More than one race2
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Donanemab
United States42
08

Study locations

1 site
  • ICON Early Phase Services Lenexa Center
    Salt Lake City, Utah 84124, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Jul 2023, 9 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 5, 2022
StartActual
Oct 4, 2022
Primary completionActual
Jul 14, 2023
CompletionActual
Jul 14, 2023
Results first posted
Oct 4, 2024
Last update
Oct 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05567159
Responsible party
Sponsor
First posted
Oct 5, 2022
Start date
Oct 4, 2022
Primary completion
Jul 14, 2023
Completion
Jul 14, 2023
Results posted
Oct 4, 2024
Last update
Oct 4, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donanemab

Start the discussion